Skip to main content
. 2022 May 13;13(12):1788–1794. doi: 10.1111/1759-7714.14455

FIGURE 3.

FIGURE 3

Kaplan–Meier curves for all patients and different sequential patterns after crizotinib progression (OS). (a) The median OS of 128 patients: 43.0 months (95% CI, 36.9–49.1 months). (b) Received other systemic treatment: 33.0 months (95% CI, 28.9–37.2 months); received the 2nd gen ALK‐TKI: 58.5 months (95% CI, 45.6–71.4 months); received the 3rd gen ALK‐TKI: 114.0 months (NR). (c) The median OS of ceritinib was 43.0 months (95% CI, 37.7–48.3 months); the median OS of brigatinib was 62.0 months (95% CI, 49.1–74.9 months); the median OS of alectinib was not reached. (d) The median OS with or without lorlatinib after first‐ and second‐generation drug resistance: 62.0 months versus 43.0 months, p = 0.014. Abbreviations: OS, overall survival; CI, confidence interval; 2nd gen, second generation; 3rd gen, third generation; ALK‐TKI, anaplastic lymphoma kinase‐tyrosine kinase inhibitor; NR, not reached; p‐values <0.05 were statistically significant